OUTCOME OF IN-VITRO FERTILIZATION AND THE AUTO ANTIBODIES AGAINST ANNEXIN V AND CARDIOLIPIN

Aziza M. A. MANSOUR *, Ahmed M. A. Rammah* and Hala M. T. EL- Mougy**

*International Islamic Center For Population Studies & Researches, Al Azhar University, Cairo.
**Biochemistry Department, Faculty of Medicine for Girls** Al Azhar University, Cairo

ABSTRACT

Objective: To evaluate the role of anti-annexin V antibodies (aANX) and anticardiolipin antibodies (ACA) as risk factors and predictors for in vitro fertilization-embryo transfer (IVF or ICSI) outcome.

Design: Prospective study.

Setting: IVF unit, Int. Islamic center for population studies and researches, Al-Azhar University, and Health centers in 10th of Ramadan city.

Subjects and Methods: Were classified into 3 groups:-

Group I: 30 women had one or more failed IVF_ET despite good morphological quality of the transferred embryos.

Group II: 30 non-pregnant women had previous history of live births.

Group III: 30 pregnant women in the first trimester as controls previously delivered normally and no previous history of pregnancy loss. All were submitted to:

1) Detailed history to eliminate any case with renal, hepatic, or metabolic diseases.
2) Complete medical examination and laboratory investigations to exclude autoimmune disease, infection, hypertension, D.M., or other endocrinal disease.
3) a- Serum antiannexin V antibodies were measured by Eliza.
   b- Serum anticardiolipin antibodies were measured by Eliza.

Results:

1) Serum antiannexin V IgG and serum anticardiolipin IgG were increased significantly in group I compared to the other groups.

2) There was no significant difference between group II&III for both parameters of antiannexin V IgG & anticardiolipin IgG with lower level in group III than group II.

Conclusion: The antiannexin V IgG & anticardiolipin IgG both can be used as predictors for IVF-ET success.

Key Words: Antiphospholipid antibodies (APA)-antiannexin (aANX)-anticardiolipin (ACA)

INTRODUCTION

Anti-phospholipid antibodies (APA) are heterogeneous group of autoantibodies that target phospholipid or phospholipid-binding proteins. Their presence was shown to induce several thrombotic states, including idiopathic recurrent spontaneous abortions. (1)

Antiphospholipid antibodies (APA) are an established cause of recurrent pregnancy loss as defective embryonic implantation is a common link between unexplained infertility and recurrent miscarriage. Interest has been focussed on the potential relationship between antiphospholipid (APL) and implantation failure after in vitro fertilization (ICSI) and embryo transfer (IVF-ET). (2)
Patients having ICSI (IVF-ET) failure show an increased incidence of antiphospholipid (APL) antibodies, antiphosphatidyl serine (IgG-APS) and anti cardiolipin (IgG-ACL). These autoantibodies may be responsible for some IVF failures. (3)

Annexins are a family of structurally related proteins which all bind to anionic phospholipids (PLs) preventing clotting on vascular phospholipid surfaces. In humans the annexins are found inside the cell. However some annexins (Annexin A1, Annexin A2 and Annexin A5) have also been found outside the cellular environment in blood. (4)

Annexin A5 plays a role in the inhibition of blood coagulation by competing for phosphatidylserine binding sites with prothrombin and also to inhibit the activity of phospholipase A1 also by competing for phosphatidylserine binding sites. (1)

Autoantibodies against annexin-V, a potent anticoagulant abundant in placental tissues, were reported to be associated with recurrent miscarriages or failures of in-vitro fertilization (IVF) attempts. (5)

Anticardiolipin Antibodies (ACL) are one of the antiphospholipid groups of antibodies. They are the most widely accepted and tested for immune factor. Approximately 80% of patients who have an antiphospholipid antibody problem will test positive for anticardiolipin antibodies, but the remaining 20% will test positive for one of the other antiphospholipid antibodies. (5)

**AIM OF STUDY**

To evaluate the role of anti-annexin V antibodies (aANX) and anticardiolipin antibodies (ACA) as predictors for in vitro fertilization-embryo transfer (ICSI) outcome.

**SUBJECTS & METHODS**

This study was carried on 90 women with age ranging between 22-42 years. They were referred from The Assisted Reproduction Unit of the International Islamic Centre for Population Studies and Researches of Al-Azhar University, Cairo, Egypt and The Health Centers in 10th of Ramadan City.

Subjects were classified into three groups:

**Group I:** Thirty women who had one or more failed in-vitro fertilization (ICSI)-embryo transfer despite good morphological quality of the transferred embryos.

**Group II:** Thirty non-pregnant women who had history of live births.

**Group III:** Thirty pregnant women (as controls) who delivered normally with no previous pregnancy losses.

* All cases were submitted to detailed history to exclude the presence of previous or recent blood; hepatic, renal, metabolic or gastrointestinal diseases which might affect the parameters to be investigated and they are non smokers.

* Complete medical examination and laboratory investigations were done to confirm the history and to exclude the presence of any autoimmune diseases e.g. systemic lupus, rheumatoid arthritis and infection, hypertension, diabetes mellitus etc.

**LABORATORY INVESTIGATIONS:**

Routine fasting and post-prandial blood glucose, serum triiodothyronin (T3) and thyroxine (T4), serum prolactin, serum progesterone, serum antiannexin V antibodies levels and serum anticardiolipin antibodies levels were performed for all subjects. Serum anti-annexin V Ig were measured by Eliza using Diapharma group Ins. (6) Serum Anti-cardiolipin IgG by Eliza using IMMCO Diagnostics USA (7)

**STATISTICAL ANALYSIS:**

Data entry was done by using personal computer (Epi-Info Program) Range, mean + SD, t test, F test...
RESULTS

Routine data in the studied groups were collected in Table I: fasting and post prandial blood sugar of all groups were found to be in the normal range, with no significant difference between the three groups. Serum triiodothyronine T3, serum thyroxine T4, prolactin and progesterone were also to be found within the normal range significant difference between the three groups, with no significant difference between the two groups.

Serum progesterone showed significant difference between group I & III and also between group II & III reflecting the physiological difference between the follicular phase of the menstrual cycle and early pregnancy.

Antannexin- V (IgG): (Table II) (Fig.1): Serum anti-annexin - V IgG in group I was 9.6 μ/ml which means a highly significant increase when compared to the other two groups (II, III).

The serum antiannexin V(IgG) in group II was 1.2 U/ml While in group III was 0.4 U/ml which mean that no significant difference between the two groups and the pregnancy control group (III) showed the lowest levels.

Anticardiolipin (IgG): (Table III) (Fig.2): Serum anticardiolipin (IgG) in group I was 15.8 GPL/ml which means a highly significant increase when compared to the other two groups (II, III).

The serum anticardiolipin (IgG) in group II was 2.07 GPL/ml while in the group III was 0.5 GPL-μ/ml which means that no significant difference between the two groups.

Correlation coefficient (r) between anticardiolipin and antiannexin V (Table III). Correlation coefficient in group I 0.01 and correlation coefficient in group II 0.00, and correlation coefficient in group III 0.00. This indicates that, there is no correlation between anticardiolipin (IgG) and antiannexin - V (IgG) in all studied groups.

Table I: Mean and SD of measured routine data in the studied groups.

<table>
<thead>
<tr>
<th></th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS (mg/dl)</td>
<td>77.9 ± 6.2</td>
<td>75.0 ± 5.2</td>
<td>77.2 ± 6.4</td>
</tr>
<tr>
<td>PPBS (mg/dl)</td>
<td>101.1 ± 9.6</td>
<td>97.1 ± 7.4</td>
<td>101.0 ± 8.6</td>
</tr>
<tr>
<td>Serum T3 (ng/dl)</td>
<td>124.2 ± 22.01</td>
<td>114.6 ± 21.04</td>
<td>122.06 ± 18.3</td>
</tr>
<tr>
<td>Serum T4 (ng/dl)</td>
<td>7.9 ± 1.1</td>
<td>7.2 ± 1.1</td>
<td>7.7 ± 1.2</td>
</tr>
<tr>
<td>Serum prolactin (ng/dl)</td>
<td>8.7 ± 2.7</td>
<td>8.09 ± 2.3</td>
<td>8.4 ± 2.7</td>
</tr>
<tr>
<td>Serum progesterone (ng/dl)</td>
<td>0.5 ± 0.2</td>
<td>0.5 ± 0.2</td>
<td>29.3 ± 8.5</td>
</tr>
</tbody>
</table>

FBS: Fasting blood sugar.
PPBS: Post-prandial blood sugar.
Table II: Mean and SD of antiannexin V (IgG) (U/ml) in the studied groups.

<table>
<thead>
<tr>
<th></th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean + SD</td>
<td>9.6 + 2.1 #</td>
<td>1.2 + 0.8</td>
<td>0.4 + 0.3</td>
</tr>
<tr>
<td>Range</td>
<td>7.5 - 19</td>
<td>0.2 - 5.2</td>
<td>0.0 - 1.3</td>
</tr>
<tr>
<td>t</td>
<td>-</td>
<td>20.0*</td>
<td>23.2 **</td>
</tr>
<tr>
<td>P</td>
<td>-</td>
<td>0.001*</td>
<td>0.001**</td>
</tr>
<tr>
<td>t</td>
<td>-</td>
<td>-</td>
<td>5.2***</td>
</tr>
<tr>
<td>P</td>
<td>-</td>
<td>-</td>
<td>0.001***</td>
</tr>
</tbody>
</table>

* Between group I and II.
** Between group II and III.
*** Between group I and III.

N.B: Despite there is a significant statistical difference between group II, III but all the results lie in the normal ranges.

The table showed a significant statistically difference between group I and the other two groups.

![Fig. 1. Mean antiannexin in the studied groups.](image-url)
Table III: Mean and SD of anticardiolipin (IgG) (GPL/ml) in the studied groups.

<table>
<thead>
<tr>
<th></th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean + SD</td>
<td>15.8 + 1.6</td>
<td>2.07 + 1.02</td>
<td>0.5 + 0.8</td>
</tr>
<tr>
<td>Range</td>
<td>13 - 20</td>
<td>0.0 - 4.8</td>
<td>0.0 - 4</td>
</tr>
<tr>
<td>t</td>
<td>-</td>
<td>39.3*</td>
<td>45.8**</td>
</tr>
<tr>
<td>P</td>
<td>-</td>
<td>0.001*</td>
<td>0.001**</td>
</tr>
<tr>
<td>t</td>
<td></td>
<td></td>
<td>6.1***</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td>0.001***</td>
</tr>
</tbody>
</table>

* Between group I and II.
** Between group II and III.
*** Between group I and III.

N.B: Despite there is a significant statistical difference between group II, III but all the results lie in the normal ranges.

The table showed a significant statistical difference between group I and the other two groups.

![Bar chart showing mean anticardiolipin in studied groups](image)

Fig. 2. Mean anticardiolipin in the studied groups.
Table IV: Correlation coefficient (r) between anticardio-lipin (IgG) and antiannexin-V (IgG) in the studied groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Coefficient</th>
<th>Std error</th>
<th>(r)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>-0.1</td>
<td>0.2</td>
<td>0.01</td>
</tr>
<tr>
<td>II</td>
<td>-0.03</td>
<td>0.1</td>
<td>0.00</td>
</tr>
<tr>
<td>II</td>
<td>-0.01</td>
<td>0.08</td>
<td>0.00</td>
</tr>
</tbody>
</table>

To prevent such assembly and subsequent thrombosis, Annexin V binds to PS on the villous syncyiotrophoblast to preclude such activity. To prevent such assembly and subsequent thrombosis, Annexin V binds to PS on the villous syncyiotrophoblast to preclude such activity.

It has been postulated that annexin V forms an antithrombotic shield around the procoagulant anionic phospholipid phosphatidylserine on the trophoblast surface which precludes trophoblast participation in phospholipids dependent coagulation reaction. It has been postulated that annexin V forms an antithrombotic shield around the procoagulant anionic phospholipid phosphatidylserine on the trophoblast surface which precludes trophoblast participation in phospholipids dependent coagulation reaction.

Annexin V is a calcium-dependent protein that binds with high affinity to phosphatidyl serine-exposed during apoptosis. Annexin V is a calcium-dependent phospholipids-binding protein that exhibits anticoagulant activity on binding to phosphatidyl serine exposed on the activated surfaces of endothelial cells and platelets, inhibiting activation of factor X and prothrombin in the blood coagulation cascade. The hallmark of the annexin super family of proteins is Ca\(^{2+}\) dependent binding to phospholipids bi-layers, a property that resides in the reversed core domain of these proteins. When PS is on the outer leaflet of acellular membrane it can support assembly of the prothrombinase complex.

DISCUSSION

Autoimmune abnormalities may be one of the possible causes for reproductive failure. The presence of abnormal, non pregnant specific autoantibody levels, i.e., anti-nuclear antibodies (ANA), anti-double stranded(ds) DNA, anti-cardiolipin antibodies (ACA), rheumatoid factor (RF), and lupus anti-coagulant (LAC) may result in a large variety of disorders; repeated pregnancy loss, endometriosis, premature ovarian failure, unexplained infertility, and repeated IVF-ET failure.

Our study demonstrates that women with recurrent IVF-ET failure (group I) showed a greater incidence of anti-ANX (IgG) antibodies than the other two groups, (group II non-pregnant women and group III pregnant women). Nonetheless, our data support the possibility that anti ANX is a risk factor for reproductive failure associated with IVF-ET failure. The Values in this study agreed with the values reported before by Matsubayashi et al., 2001 who hypothesized that anti ANX might be involved in reproductive failure if by their presence the antithrombotic shield is compromised. Since...
annexin V had been described as forming a fetal-maternal interface necessary to ensure successful pregnancy, their findings support the possibility that the presence of aANX is a potential risk factor for reproductive failure.

In an animal model, administration of Annexin V inhibited thrombus formation and fibrin accretion. Infusion of anti ANX decreased the availability of Annexin V to bind to the trophoblast surface, thereby causing placental thrombosis, necrosis, and fetal loss. These data support a pathogenic role for anti ANX in reproductive failure.

Our study is in contrast with only one study of Gris et al, 2000 who showed that anti ANX (IgG) is an independent risk factor of unexplained fetal loss between 10 and 24 weeks of pregnancy.

Interest has focussed also on the potential relationship between anticardiolipin antibodies and implantation failure after in vitro fertilization and embryo transfer (IVF-ET).

Our study had demonstrated that women with recurrent IVF-ET failure (group I) showed a greater incidence of ACL antibodies (15.81 GPL/ml) than the other two groups, (GROUP II) non-pregnant women (2.07 GPL/ml) and (GROUP III) pregnant women (0.58 GPL/ml). Values in this study agreed with the values reported before by the previous study published by Matsubayashi et al., 2001.

Anti-cardiolipin has shown to bind embryo trophectoderm and to inhibit trophoblast proliferation and development. Indeed, patients with aCL (IgG) in one IVF problem were found to have morphologically abnormal embryos. In addition, pre-implantation embryos derived from ACL-injected mice exhibited morphological abnormalities and failed to implant to healthy recipients. Other similar studies reported that women with IVF failures have an increased incidence (10-32%) of antiphospholipid (aPL) antibodies when compared with successful reproducing women or a normal population (0-5%).

Our study contradicts the study of Chilcott et al., 2000 who reported that despite of high prevalence of aPL in women referred for IVF, these antibodies do not influence the outcome of an IVF cycle. So Chilcott et al., 2000 concluded that the routine screening of women undergoing IVF for aPL is not justified.

However, as our study recommends: Tan et al., 2005 stated that ACL antibodies and lupus anticoagulant were the most frequent investigations suggested in recurrent IVF treatment failure in the UK followed by hysteroscopy then karyotyping. Antiphospholipid antibodies are an established cause of recurrent pregnancy loss, and defective embryonic implantation is a common link between unexplained infertility and recurrent miscarriage. So, Several investigators have advocated testing women undergoing in-vitro fertilization (IVF) for APA & Serum Anti-cardiolipin Antibodies; Serum immunological factors may play a part in clinical pregnancy outcome in IVF-ET.

Antibodies to the negatively charged phospholipids and cardiolipin, has been reviewed by Rand et al, 1998 and discussed by Rote et al, 1998. They have reported that anti-PS or anti-cardiolipin can displace Annexin V from the trophoblast surface and thereby expose procoagulant membrane sites to stimulate thrombosis.
REFERENCES


